EVALUATION OF NEPAFENAC EYE DROPS IN PREVENTION OF MACULAR EDEMA FOLLOWING CATARACT SURGERY IN PATIENTS WITH DIABETIC RETINOPATHY

Thesis

Submitted for Partial Fulfillment of M.Sc *In Ophthalmology*

By

Kamal Farrag El-Sayed Othman

(M.B., B.Ch)

Supervised by

Prof. Dr. Magda Mohamed Mahmoud Samy

Professor of Ophthalmology
Faculty of Medicine - Ain Shams University

Dr. Sameh Hany Abdel Rahman

Lecturer of Ophthalmology
Faculty of Medicine - Ain shams University



Faculty of Medicine Ain Shams University 2016

بِسْمِ ٱللَّهِ ٱلرَّحْمَٰنِ ٱلرَّحِيمِ ﴿ رَبِّ إِنِي لِمَا أَثْرَالْتَ لِكَ مِنْ خَيْرٍ فَقِيرٍ ﴾

سُورَةُ القَصَصِ- ٢٤

صَدَقَ ٱللَّهُ ٱلْعَظِيمُ

Acknowledgement

First of all, I would like to express my deepest gratitude to "Allah" the most Merciful who is praised for all his favors and blessings.

I would like to thank *Prof. Dr. Magda Mohamed Mahmoud Samy, professor of ophthalmology, Faculty of Medicine, Ain Shams University,* for her great help and support.

I would like to thank Lecturer *Dr. Sameh Hany Abdel Rahman, Lecturer of Ophthalmology, Faculty of Medicine, Ain Shams University* for his kind assistance and patience.

Also I would like to thank all my family for their support and prayers.

Kamal Farrag

List of Contents

Title Page				
•	List of Abbreviations	. I		
•	List of Tables	III		
•	List of Figures	IV		
•	Introduction	. 1		
•	Aim of the Work	.4		
•	Review of Literature			
	- Diabetic Macular Edema	. 5		
	- Pseudophakic Macular Edema	18		
	- OCT and macula	28		
	- Pharmacology of Nepafenac	.40		
•	Patients and Methods	46		
•	Results	.52		
•	Discussion			
•	Conclusions68			
•	Recommendations	70		
•	Summary	71		
	References	73		
•	Arabic Summary			

List of Abbreviations

um Micrometer **3-D**Three-dimension BCVA.....Best corrected visual acuity BRBBlood-Retina Barrier **CC**Choriocapillaris CME.....Cystoid macular edema COX.....Cyclooxygenase **DM**.....Diabetes mellitus **DME**Diabetic macular edema **DR**diabetic retinopathy **ECCE**.....Extracapsular cataract extraction **ELM** External limiting membrane **ERM**Epiretinal membrane **ETDRS**.....Early treatment diabetic retinopathy study **FA**.....Fluorescein angiography FAZ.....Foveal avascular zone GCLGanglion cell layer **HS**Highly significant ICCEIntracapsular cataract extraction **ILM**Internal limiting membrane **INL**.....Inner nuclear layer IOPIntraocular pressure **IPL**.....Inner plexiform layer **IS/OS**Inner and outer segment **LECs**.....Lens epithelial cells minimal **LogMAR**.....Logarithm angle of resolution

List of Abbreviations

ME......Macular edema **MFT**.....Mean foveal thickness mm.....millimeter **MMFT**.....Minimal mean foveal thickness NFL.....Nerve fiber layer NS......Non-significant NSAID.....Nonsteroidal anti-inflammatory drug **OCT**.....Optical coherence tomography **ONL**Outer nuclear layer **OPL**.....Outer plexiform layer **P**.....P value **PC IOL**Posterior chamber intraocular lens **PCO**Posterior capsular opacification **PMMA**.....Polymethyl methacrylate **PRP**.....Pan retinal photocoagulation **PSC**......Posterior subcapsular cataract **r**......Correlation coefficient RLARetinal leakage analyzer RNFLRetinal nerve fiber layer RPERetinal pigment epithelium S.....Significant SD.....Standard deviation SD-OCTSpectral domain-OCT SPSS.....Statistical Package of Social Science Software program TD-OCTTime domain-OCT **VEGF**Vascular endothelial growth factor

List of Tables

Table No.	Title Page
Table (1):	Patterns of macular edema37
Table (2):	Description of variables within the
	whole sample 55
Table (3):	Continue description of variables
	within the whole sample56
Table (4):	Comparison between both groups
	regarding macular thickness 57
Table (5):	Comparison between both groups
	regarding BCVA58

List of Figures

Figure No.	Title Page
Fig. (1):	Exudates8
Fig. (2):	Pathology of diabetic retinopathy9
Fig. (3):	Diabetic retinal capillary bed with many acellular capillaries due to occlusion; remaining capillaries are dilated and show loss of pericytes and an increased number of endothelial cells
Fig. (4):	Clinically significant macular edema 17
Fig. (5):	SD-OCT, Spectralis 3D image of retina from a healthy volunteer 28
Fig. (6):	OCT images of the macular region 30
Fig. (7):	Computer image-processing to quantitatively measure retinal features
Fig. (8):	Cystoid macular edema34
Fig. (9):	DME with serous detachment (Right and left eye of the same patient) using SD-OCT, Cirrus
Fig. (10):	DME with marked retinal thickening and extensive areas of low intraretinal reflectivity consistent with fluid accumulation and macular cysts. Highly reflective intraretinal dots (right side of the scan) representing hard lipid retinal exudates

List of Figures

Figure No.	Title Page	е
Fig. (11):	OCT demonstrates improvement in CME after the use of nepafenac thrice daily for 14 days	
Fig. (12):	3D pyramids showing sex distribution in both groups	
Fig. (13):	Pie chart showing the stages of DR 54	
Fig. (14):	Bar chart showing the mean of central subfield macular thickness (µm) in both groups pre-operatively and 30 day post-operatively	
Fig. (15):	Bar chart showing the mean of BCVA in both groups pre-operatively and 30 day post-operatively	

Ontroduction

Introduction

Cystoid Macular Edema (CME) represents the most common cause of unexpected visual loss or sub-optimal visual outcome after cataract surgery. CME may occur following complicated or uncomplicated cataract surgery, without significant race or gender predilection (Ray and D'Amico, 2002).

In United States, the incidence of Clinically Significant Macular Edema (CSME) with decreased vision following cataract surgery is only about 0.2-1.4% after modern phacoemulsification surgery. The percentage was higher in older techniques of cataract surgery, where CME could occur in up to 20-60% of eyes (Bélair et al, 2009; Shelsta and Jampol, 2011).

The incidence of macular changes following cataract surgery in diabetic patients is higher, especially those with pre-existing retinopathies, compared with non-diabetic individuals (*Johnson*, 2009).

The rate of development of macular edema in diabetic populations (with or without diabetic retinopathy) varies across studies, ranging from 31% to 81% at various time points following cataract extraction (*Krepler et al.*, 2002).

OCT provides a quantitative description of macular edema in the form of retinal thickness and volume. OCT is highly more sensitive than fundus examination by slit-lamp biomicroscopy in detection of any small changes in retinal thickness (*Hee et al.*, 1995).

Nepafenac ophthalmic suspension 0.1% is a topical NSAID which was prescribed for the treatment of pain and inflammation associated with cataract surgery. Nepafenac is a prodrug that rapidly penetrates the comea and is deaminated to form the active metabolite, amfenac, by intraocular hydrolases within ocular tissues (Gaynes and Onyekwuluje, 2008).

Amfenac as well as nepafenac are potent inhibitors of the cyclooxygenase enzyme isoforms (COX1 and COX2) (Lane, 2006).

Topical nepafenac also may inhibit choroidal neovascularization (CNV) and ischemia-induced retinal neovessels in rats by decreasing the production of VEGF. Topical ocular nepafenac also had prevented the development of induced panretinal edema in rabbit (Takahashi et al., 2003).

Subjects and Methods:

Thirty eyes of diabetic patients with cataract who are candidates for phacoemulsification and posterior chamber intraocular lens (IOL) implantation were divided into two groups; Group 1 (control group) consisted of 15 eyes and Group 2 (nepafenac group) consisted of 15 eyes.

Preoperative evaluation will be performed including best corrected visual acuity (BCVA), slit-lamp biomicroscopy, indirect ophthalmoscopy, intraocular pressure (IOP) measurement, and biometry to calculate IOL power and measurement of macular thickness using OCT.

Postoperative examinations are to be performed one day, one week and one month after surgery. All of the patients will be subjected to ophthalmological examination including BCVA, biomicroscopy, IOP measurement, indirect ophthalmoscopy.

OCT will be performed one month postoperatively. Exclusion criteria are subjects who have dense cataract or subjects with prior intraocular surgery of any type, history of uveitis, or the presence of any retinal or choroidal disease, other than diabetes, that could affect retinal thickness.

Aim of the Work

Aim of the Work

The aim of this study is to assess the effect of using nepafenac ophthalmic suspension to prevent the development of macular edema in diabetic individuals following uneventful phacoemulsification and posterior chamber intraocular lens (PC IOL) implantation.